Skip to content
Triangle logo TriangleGet started
← Back to this collection

PUBLICATIONS · 26092816

Patient-reported outcomes with adjuvant exemestane versus tamoxifen in premenopausal women with early breast cancer undergoing ovarian suppression (TEXT and SOFT): a combined analysis of two phase 3 randomised trials.

Open original source → · Download preserved record

Bibliographic metadata only. No full-text article or abstract is reproduced. Absence of a captured notice is not confirmation that a publication is clear of corrections or retractions.

Journal
Lancet Oncol
Publication date
2015 Jul
First author
Bernhard J

Publication notices

absence is not clearance
true
has correction metadata
false
has expression of concern metadata
false
has retraction in link
false
pubmed marks article retracted
false
pubmed marks retraction notice
false
relationships
  1. citation
    Lancet Oncol. 2015 Jul;16(7):749-51. doi: 10.1016/S1470-2045(15)00052-2.
    note
    Source null
    related pmid
    26092819
    relationship
    Comment in

Authors and identifiers

  1. name
    Bernhard J
    type
    Author
  2. name
    Luo W
    type
    Author
  3. name
    Ribi K
    type
    Author
  4. name
    Colleoni M
    type
    Author
  5. name
    Burstein HJ
    type
    Author
  6. name
    Tondini C
    type
    Author
  7. name
    Pinotti G
    type
    Author
  8. name
    Spazzapan S
    type
    Author
  9. name
    Ruhstaller T
    type
    Author
  10. name
    Puglisi F
    type
    Author
  11. name
    Pavesi L
    type
    Author
  12. name
    Parmar V
    type
    Author
Complete bibliographic record and source provenance
authors
  1. name
    Bernhard J
    type
    Author
  2. name
    Luo W
    type
    Author
  3. name
    Ribi K
    type
    Author
  4. name
    Colleoni M
    type
    Author
  5. name
    Burstein HJ
    type
    Author
  6. name
    Tondini C
    type
    Author
  7. name
    Pinotti G
    type
    Author
  8. name
    Spazzapan S
    type
    Author
  9. name
    Ruhstaller T
    type
    Author
  10. name
    Puglisi F
    type
    Author
  11. name
    Pavesi L
    type
    Author
  12. name
    Parmar V
    type
    Author
bibliography ids
  1. nci-bib-fb699ba2488b50fd6f713e32
book metadata
content sha256
dc2b217d5d22390aa956ca22fed423b62c0e4f975a2375849fb114e668e0796d
document type
citation
dois
  1. 10.1016/S1470-2045(15)00049-2
electronic publication date
display
2015 Jun 16
precision
day
year
2015
evidence scope
bibliographic_metadata_only
id
pubmed:26092816
immutable id
pubmed:26092816@dc2b217d5d22390aa956ca22fed423b62c0e4f975a2375849fb114e668e0796d
journal
abbreviation
Lancet Oncol
issn electronic
1474-5488
issn print
1470-2045
issue
7
name
The Lancet. Oncology
nlm unique id
100957246
pages
848-58
volume
16
languages
  1. eng
notices
absence is not clearance
true
has correction metadata
false
has expression of concern metadata
false
has retraction in link
false
pubmed marks article retracted
false
pubmed marks retraction notice
false
relationships
  1. citation
    Lancet Oncol. 2015 Jul;16(7):749-51. doi: 10.1016/S1470-2045(15)00052-2.
    note
    Source null
    related pmid
    26092819
    relationship
    Comment in
outcomes validated
false
pmid
26092816
provenance
batch id
74265f1b641f04cf2d05
provider
NCBI PubMed ESummary
record sha256
33e6aad69ac441f79b17890eabc2a47cd3b8de4d300c6f1f1845744509d33c6a
response sha256
193df6bb6d2ac41af73dc445bf8171fe8076a8c8a5e98882a3d6a1ada428b0f0
retrieved at
2026-09-09T23:47:10.134322+00:00
publication date
display
2015 Jul
precision
month
year
2015
publication types
  1. Clinical Trial, Phase III
  2. Comparative Study
  3. Journal Article
  4. Randomized Controlled Trial
  5. Research Support, N.I.H., Extramural
  6. Research Support, Non-U.S. Gov't
record status
PubMed - indexed for MEDLINE
schema version
1.0
source url
https://pubmed.ncbi.nlm.nih.gov/26092816/
title
Patient-reported outcomes with adjuvant exemestane versus tamoxifen in premenopausal women with early breast cancer undergoing ovarian suppression (TEXT and SOFT): a combined analysis of two phase 3 randomised trials.

Preserved source evidence · Not medical advice